On June 5, 2025 Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") reported that it will participate in and present at the 46th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 9, 2025, at 1:20 PM ET (Press release, Summit Therapeutics, JUN 5, 2025, View Source [SID1234653752]). Members of the Summit management team will participate in a fireside chat presentation providing a corporate overview and update on the progress of our organization, including the development of our innovative investigational bispecific antibody, ivonescimab.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available live from our website: www.smmttx.com. An archived version of the presentation will be available on our website following the presentation.

On June 5, 2025 Mission Bio, a leader in single-cell multi-omics solutions for precision medicine, reported the launch of its Single-Cell Genotype and Targeted Gene Expression assay, expanding the capabilities of its Tapestri Platform to become the only commercial solution that delivers simultaneous genotype and targeted gene expression profiling from over 10,000 single cells (Press release, Mission Bio, JUN 5, 2025, View Source [SID1234653751]). The assay, which can be leveraged for Phase 2 or 3 trials to home in on patients most likely to benefit from a cancer therapy, will be unveiled at the European Hematology Association (EHA) (Free EHA Whitepaper) meeting in Milan, Italy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Single-Cell Genotype and Targeted Gene Expression is available through Mission Bio’s Pharma Assay Development (PAD) services, where the company’s experts provide end-to-end support from custom single-cell assay design and development to data interpretation and assay transfer. The multi-modal assay has three primary applications: helping understand therapeutic resistance, designing next-generation T-cell therapies, and improving patient selection in clinical development.

In particular, the Single-Cell Genotype and Targeted Gene Expression assay addresses critical challenges in oncology drug development, where obtaining the complete picture of tumor heterogeneity and therapeutic resistance mechanisms has been hampered by limitations in existing and disparate methods. By capturing both genomic mutations and targeted gene expression changes in the same cell, the enhanced Tapestri Platform enables pharmaceutical researchers to gain a comprehensive, high-resolution view of cancer cell behavior and treatment response – allowing companies to derisk late-stage development.

"The majority of clinical failures in hematologic cancer drug development occur in Phases II and III, often due to inadequate patient response and lack of predictive biomarkers for patient stratification," said Brian Kim, CEO of Mission Bio. "We’re directly addressing the urgent need to understand which patients will respond to which drugs at what time, by adding this custom capability to our portfolio of tools. It builds on our continuing mission to offer the tools that drug developers need to understand drug impact at the single-cell level and de-risk late-stage clinical trial failures."

The new Single-Cell Genotype and Targeted Gene Expression assay also features sample multiplexing capabilities, reducing the cost of single-cell analysis by approximately 60% compared to using multiple technologies to generate similar insights. Tapestri users have previously developed bespoke capabilities to leverage targeted gene expression alongside single-cell genotype and multi-omics, an early demonstration of the value of Mission Bio’s newly integrated approach. Among multiple use cases has been the deconvolution of clonal architecture and tracking resistant subclones under therapeutic pressure in AML. In the future, Mission Bio’s PAD team will enable true multi-omics by adding immunophenotyping to the Single-Cell Genotype and Targeted Gene Expression assay.

Mission Bio and Partners Presenting at EHA (Free EHA Whitepaper)

EHA will feature two oral presentations from Mission Bio’s academic partners featuring use of the Tapestri Platform.

Interrogating clonal evolution of NPM1-mutant AML through genetic and genomic approaches

Dr. Linde Miles, assistant professor at Cincinnati Children’s Hospital Medical Center
Friday, 13 June, 15:45 – 16:15 CEST
Amber Hall 7+8
Session 3 Keynote lecture: Cell fate and cell plasticity in normal and malignant hematopoiesis

Dr. Lars Velten, Centre for Genomic Regulation (CRG) Barcelona, Spain
Saturday, 14 June, 14:00 – 14:20 CEST
Brown Hall 2
Both Dr. Miles and Dr. Velton will also present at Mission Bio’s EHA (Free EHA Whitepaper) evening event, The Power of One: A Night of Multi-Omics Discovery @ EHA (Free EHA Whitepaper) 2025, Friday, June 13, 2025 at 7:00 PM.

Late-Breaking Oral Session: INCA33989 is a Novel, First In Class, Mutant Calreticulin-Specific Monoclonal Antibody that Demonstrates Safety and Efficacy in Patients with Essential Thrombocythemia (ET)

Dr. John Mascarenhas, Icahn School of Medicine at Mount Sinai
Sunday, June 15, 2025, 09:15 CEST
Location TBD
Mission Bio will also be presenting six posters at EHA (Free EHA Whitepaper) in Poster Hall, beginning on Saturday, 14 June, 18:30 CEST.

CXCR4 Expression In Aml Blasts And Its Impact On CXCR4 Inhibitor Efficacy During Consolidation Therapy: Results From The Sal Blast Trial
Dr. Enise Ceran (Heidelberg, Germany)
Single Cell Multi-omic Analysis Uncovers Molecular And Clonal Events Associated With Ruxolitinib Treatment Response In Myelofibrosis
Dr. Sebastiano Rontauroli (Modena, Italy)
Characterization Of CD9 As A Novel Marker For Disease-Propagating Stem Cells In Myelofibrosis
Dr. Lara Tavernari (Modena, Italy)
Deciphering Clonal Heterogeneity In Aml Npm1 Through Single-Cell Multi-Omic
Dr. Wencke Walter (Munich, Germany)
Three Patterns Of Molecular Minimal Residual Disease Kinetics In Venetoclax + Azacitidine (V+A) Treated Acute Myeloid Leukemia (AML) Patients
Dr. Jiří Mayer (Brno, Czechia)
High-Throughput And Highly Sensitive Single Cell Genotyping With Simultaneous Chromatin Accessibility Profiling In Myeloid Precursor Conditions
Dr. Masanori Motomura (Kyoto, Japan)
For more information about Mission Bio’s Targeted Single-Cell Gene Expression assay and Pharma Assay Development services, please visit missionbio.com.

Visit Mission Bio at EHA (Free EHA Whitepaper) at booth M.10.

On June 5, 2025 MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, reported a new partial response (PR) was identified in a patient after 20 months of treatment in its Phase 2 THIO-101 clinical trial evaluating ateganosine (THIO), sequenced with Regeneron’s immune checkpoint inhibitor (CPI) cemiplimab (Libtayo) in patients with advanced non-small cell lung cancer (NSCLC) who are resistant to immune therapy and chemotherapy (Press release, MAIA Biotechnology, JUN 5, 2025, View Source [SID1234653750]). A partial response is defined as a decrease in tumor size of at least 30%.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The patient remained on treatment and we observed stable disease for more than twenty months before the partial response was identified, highlighting the efficacy, safety and low toxicity of the treatment. Extended-term responses like this are not often seen in heavily pretreated patients in hard-to-treat diseases such as NSCLC, where the prognosis for the advanced-stage of the disease is typically poor," said MAIA Chairman and CEO Vlad Vitoc, M.D. "We confirmed this response with a second scan, and we are highly confident that ateganosine could become an outstanding therapeutic alternative for third-line NSCLC patients."

THIO-101 third line (3L) data cutoff from May 15, 2025, showed median overall survival (OS) of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine in parts A and B of the trial. At the data cutoff, the patient with the longest survival in the trial had completed 32 cycles of therapy and had 24.3 months survival. Studies of standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months.1

MAIA has announced the trial design for an expansion of its THIO-101 pivotal Phase 2 trial in NSCLC to assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous CPI treatment and chemotherapy.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

On June 5, 2025 Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, reported a strategic partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) to co-develop and commercialize minimal residual disease (MRD) assays for solid tumors on QIAGEN’s QIAcuity digital PCR platform (Press release, Qiagen, JUN 5, 2025, View Source [SID1234653749]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This collaboration aims to deliver highly sensitive, cost-effective, and decentralized MRD testing solutions that enable oncologists to monitor cancer recurrence and guide personalized treatment decisions using minimally invasive blood samples.

"Partnering with QIAGEN enables Tracer to bring our solid tumor MRD expertise to a broader market using a robust digital PCR platform in QIAcuity," said Mark Kaganovich, CEO of Tracer Biotechnologies. "With QIAcuity’s sensitivity and scalability, we can deliver high-quality companion diagnostics that integrate seamlessly into clinical workflows and offer new options to oncologists and patients."

Tracer offers two complementary MRD solutions:

Tracer dPCR, a tumor-informed, multiplexed digital PCR assay that allows institutions to run bespoke MRD tests internally using their own digital PCR instruments;
Tracer WGS, an AI-powered whole-genome ctDNA platform that enables ultra-sensitive tumor-agnostic detection and tracking with no need for prior tissue.
"This new partnership represents an important step in further establishing QIAGEN’s major role in oncology. We are bringing innovative MRD technologies into drug development through our companion diagnostic partnerships," said Jonathan Arnold, Vice President, Head of Partnering for Precision Diagnostics at QIAGEN. "In particular, we want to strengthen our scalable, cost-effective solutions based on our QIAcuity digital PCR system and enable our pharmaceutical partners to use MRD insights for guiding personalized treatment decisions for cancer patients."

Tracer’s mission is to turn every digital PCR machine and next-generation sequencer into a sensitive MRD assay—empowering institutions, pharmaceutical companies, and clinicians with the tools to decentralize testing, accelerate treatment decisions, and personalize cancer care.

On June 5, 2025 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) reported the placement of 5,918,000 H shares under its general mandate, representing approximately 2.54% of the enlarged share capital of the Company post the placement (Press release, Kelun, JUN 5, 2025, View Source [SID1234653748]). The shares were placed at HK$331.8 per share, raising net proceeds of approximately US$250 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Highlights of the placement include:

The offering was widely recognized by a broad-based investors including domestic and international institutional investors. The transaction was multiple times oversubscribed with robust participation from high-quality investors including global long only funds, sovereign wealth funds, and healthcare specialist funds;
Due to the robust booking demand, the deal size was upsized from the initially targeted US$200 million at launch to US$250 million, making it the largest follow-on offering in the biopharma industry in the Hong Kong market over the past 12 months;
The final offer price represents a 7.58% discount to the last closing price and a 0.89% premium to the average closing price over the past five trading days.
The Company primarily intends to use the net proceeds of the placing (i) for the research and development, clinical trials, registration filings, manufacturing and commercialization of its products; (ii) to enhance its internal research and development technology capabilities, strengthen external collaboration, and expand its product pipeline portfolio.

Dr. Michael Ge, CEO of Kelun-Biotech, commented: "We are pleased to see continued support from our key existing shareholders, alongside the addition of new, high-profile investors. This reflects the strong recognition of Kelun-Biotech’s long-term investment value by international capital markets and specialist investors. With the support of this financing, we aim to further strengthen our pipeline strategy and accelerate global clinical development. This will enable us to unlock the potential of cutting-edge therapies and deliver innovative treatments to benefit more cancer patients."